

March 3, 2015

Dear Solos Endoscopy, Inc. Shareholders,

I am very pleased to be able to communicate with our loyal shareholders directly and to give you an update on our progress this year.

Solos Endoscopy, Inc. has been at the forefront of breakthrough medical devices and technologies for the treatment and management of diseases for over 25 years. The Company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.

On Friday February 20, 2015, a successful live demonstration of Solos Endoscopy's MammoView® Breast Endoscopy procedure was performed at the Dr. Susan Love Research Foundation Symposium in front of some of the most prominent and highly respected surgeons from around the World that specialize in breast cancer diagnostic procedures. The purpose of the MammoView® procedure at the Symposium was to demonstrate to the attendees the most efficient techniques and procedures to introduce the Solos ductoscope into the breast. It has been determined by many hospitals across the Country that MammoView® Breast Endoscopy System can help give women the best prognosis for recovery by detecting breast cancer significantly faster than conventional methods. The MammoView® Breast Endoscopy System allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods. Solos management has reported that MammoView® product sales has increased as a percentage of gross sales and in the past 18 months the Company has continued to receive additional MammoView® orders from hospitals nationwide.

In 2014, Solos Endoscopy received its ISO 13485:2003 Certification from TUV SUD America. The Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to place the CE Mark on the majority of its endoscopic instruments including the MammoView® devices. The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada. The Certification came at the conclusion of a lengthy Audit with TUV SUD America in 2013. The Audit included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's

Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282).

Health Canada's Medical Device Bureau (MDB) completed its evaluation of Solos Endoscopy's instruments and has classified its devices as Class II medical devices. The Medical Device Bureau reviewed the MammoView® Dilator Set, MammoView® Cytology Retrieval Kit, MammoView® Introducer Set, and the Microendoscope Ductoscope. Solos Endoscopy needed to complete the review to apply for Canada's Medical Device License. The Company has delayed the filing of its application while management has been evaluating its multiple options for the Canadian market. The Company is currently working with Spectrum Medical Market Consultants to act as its representative in Canada for its endoscopic instruments including the MammoView® devices.

Solos Endoscopy experienced significant back orders in 2014 due to supply issues related to a component manufacturer. In addition, sales have been slower in the first quarter due to weather related issues in the New England area. As a result of the back orders, the Company's cash flow and sales declined. Management continues to work with its suppliers in an effort to resolve outstanding issues regarding production. In the last six months, fifteen new hospitals have begun to carry Solos Endoscopy instruments. This includes a select number of hospitals who are now carrying the MammoView® product line.

Solos Endoscopy, as a public Company, continues to update its shareholders through regular postings on www.otcmarkets.com and through Company press releases. To learn more information about the Company and its products visit www.solosendoscopy.com. I want to thank all our loyal shareholders and I look forward to a successful 2015.

Regards,



Robert Segersten

President and CEO

Solos Endoscopy, Inc.

Certain statements in this document may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this document, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.